Verrica Provides Business and Operational Update
20 déc. 2024 07h00 HE
|
Verrica Pharmaceuticals Inc.
-- Dispensed applicator units in the fourth quarter of 2024 have exceeded the complete prior quarter even with significant cost reductions in sales and operational infrastructure -- Observed...
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 déc. 2024 16h15 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
06 déc. 2024 08h00 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Announces Pricing of $42.0 Million Public Offering
21 nov. 2024 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Announces Proposed Public Offering
20 nov. 2024 16h05 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
04 nov. 2024 16h05 HE
|
Verrica Pharmaceuticals Inc.
– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– ...
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
24 oct. 2024 07h00 HE
|
Verrica Pharmaceuticals Inc.
- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance - WEST CHESTER,...
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
02 oct. 2024 07h30 HE
|
Verrica Pharmaceuticals Inc.
- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond...
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
04 sept. 2024 07h30 HE
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin...
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
14 août 2024 07h45 HE
|
Verrica Pharmaceuticals Inc.
- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH’s distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces...